Trial Comparison Will Help In Treatment Of Arthritis
Trial Comparison Will Help In Treatment Of Arthritis
www.accessibility.com.au
Source: Lancet
Country of Origin: UK
Date originally Published: 11-Feb-07
Date added to Accessibility: 24-Feb-07
Incidence of upper gastrointestinal clinical events in patients with arthritis on the COX-2 inhibitor etoricoxib are fewer than in those patients on the NSAID* diclofenac, according to an Article in this week's issue of The Lancet. This information will assist patients with arthritis and their physicians in making decisions about pain management.
NSAIDS are often taken long term by arthritis patients. However, they significantly increase the risk of upper gastrointestinal clinical events such as bleeding ulcers. The incidences of upper gastrointestinal clinical events have been shown to be significantly less with COX-2 than traditional NSAIDS. However, previous trials have not simulated standard clinical practice because gastrointestinal protective therapies - eg, proton pump inhibitors (PPIs) - were not allowed.
Loren Laine (University of Southern California Keck School of Medicine, Los Angeles, USA) and colleagues analyse data from three randomised trials from the MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-term) programme† to assess the effects of COX-2 inhibitors versus traditional NSAIDS on upper gastrointestinal outcomes in a setting that simulates real-world practice, in which patients with gastrointestinal risk factors were encouraged to use protective PPI therapy and those with cardiovascular risk were encouraged to take low-dose aspirin. Overall, upper gastrointestinal clinical events were significantly less common with etoricoxib than with diclofenac, but not in the more serious complicated events‡. The treatment effects did not differ significantly in individuals using PPIs or aspirin.
The authors conclude: "The results of the MEDAL programme provide new information about upper gastrointestinal clinical events and symptoms to assist arthritis patients and their physicians to make decisions regarding NSAID use."
In an accompanying Comment, Joost Drenth and Freek Verheugt (Radboud University Nijmegen, Netherlands) state: "Though eterocoxib reduced upper gastrointestinal events, the effect was only small as 259 patients need to be treated to prevent one uncomplicated gastrointestinal event. The alternative, addition of a PPI to standard NSAID might be less expensive, potentially less cardiotoxic, and advantageous in terms of reducing dyspepsia, but here confirmation needs a randomised trial." (Quote by email; not in published paper)
About Us
Accessibility.com.au was established in May 1999 by Nick Morris and David Goding, two of Australia's leading access consultants. They recognised a need for an Australian resource that provided comprehensive and ready access to information on accessible venues, facilities, services, transport, mobility aids and news. It didn't take long for it to become the most visited disability information website, with as many as 30 000 hits per month by 2005.
In early 2006, Nick and David began collaborating with Andrew Wilshire, a successful IT and internet entrepreneur, and Kerrie Thomsen, a leading occupational therapist with expertise in independent living products. They wanted to expand the scope of accessibility.com.au, to create the premier health care information and accessible product resource for people with a disability, their families, carers and health professionals. They envisaged accessibility.com.au becoming the place that people could confidently go to find high quality information on access, a range of health topics and products for independent living.
In mid 2006, a team of professionals was employed to further develop the website, adding more information and crafting it to a wider audience. Through a process of systematic review, they ensured that only the most valuable information was selected to be displayed on accessibility.com.au. They also developed a unique and intuitive system of information categorisation, making it easy for visitors to navigate through the site and find exactly what they need.
As the new accessibility.com.au evolves from its launch in 2007, we will seek engagement with the community at all levels, with the objective of meeting a range of diverse needs.
The internet has created opportunities for connection with people, information, access friendly tourism and products like never before, and so there has never been a better time to develop a premium online resource like accessibility.com.au.
Contact Us
Phone: 1300 ACCESS (1300 222 377)
Hours: 9am - 6pm (AEST) 6 days a week (Mon to Sat)
Mail:
Accessibility Online Pty Ltd
Suite 105, 56 Bowman Street
Pyrmont, NSW 2009
Australia
© accessibility online 2009
Votes:3
Comments: 0